Rituximab Efficacy in the Treatment of Children with Chronic Immune Thrombocytopenic Purpura
Rituximab Efficacy in the Treatment of Children with Chronic Immune Thrombocytopenic Purpura
复制标题
DOI：
10.3109/08880018.2014.930766
复制
发表时间：
2014-09-01
影响因子：
1.7
通讯作者：
Ramim, T.
中科院分区：
文献类型：
--
作者：
Ansari, Sh;Rostami, T.;Ramim, T.
背景：免疫性血小板减少性紫癜(ITP)的治疗药物有多种，包括糖皮质激素、静脉注射免疫球蛋白、免疫抑制药，甚至脾切除术。如果失败，应考虑将利妥昔单抗作为这些患者使用的药物之一。方法：对阿里阿斯哈尔医院血液肿瘤门诊就诊的患者进行前瞻性研究。对18例患者进行了至少3~5年的随访。结果：治疗4周后，18例患者中仅6例(33/3%)获得完全缓解(Plt>；100,000)，大部分患者(67/66%)无反应。在治疗后6个月和36个月进行的后续调查中，患者反应的百分比下降到22/2%。结论：利妥昔单抗治疗慢性ITP具有较好的安全性。然而，该药物对患者血小板计数的预期改善没有显著影响。看来单一治疗对慢性ITP无效，建议联合其他辅助治疗。
Background: There are several medications for treatment of immune thrombocytopenic purpura (ITP), including corticosteroids, intravenous immunoglobulin, immunosuppressive drugs, and even splenectomy. In case of failure, Rituximab as one of the medications used in these patients should be considered. Method: This Case-series study was conducted prospectively in patients who were referred to Hematology & Oncology Clinic of Ali Asghar Hospital. Eighteen Patients were followed up for at least 3-5 years. Results: Four weeks after treatment, only in 6 patients (33/3%) of 18 patients, complete response (Plt > 100,000) were obtained and most patients (67/66%) had no appropriate response. In subsequent surveys conducted at 6 and 36 months after treatment, the percentage of patients responding fell to 22/2% hit. Conclusion: The results of this study demonstrate proper safety of Rituximab in the treatment of chronic ITP. However, the drug had no significant effect on the expected improvement in platelet count of patients. It seems that monotherapy is ineffective in the treatment of chronic ITP and combination with other complementary therapies is recommended.